Semaglutide has a well-characterized safety profile from large-scale clinical trials. Gastrointestinal side effects are the most common, particularly during dose escalation.
Medical Disclaimer: This page is for informational and research purposes only. It does not constitute medical advice. Always consult a qualified healthcare professional before using any research chemical or peptide. Semaglutide is not FDA-approved for human use (unless noted).
The most common side effect, reported in up to 44% of patients in clinical trials. Typically most pronounced during dose escalation and improves over time.
Reported in approximately 24% of patients in clinical trials. Usually mild to moderate and decreases with continued use.
Reported in approximately 30% of patients. Typically transient and improves as the body adapts.
Reported in approximately 24% of patients. May alternate with diarrhea.
Mild to moderate abdominal discomfort or cramping reported by many patients.
Significant reduction in appetite is both a therapeutic effect and a reported side effect.
Rare but serious. Patients with history of pancreatitis should not use semaglutide. Seek immediate medical attention for severe abdominal pain.
Increased risk of gallstones and cholecystitis, particularly with rapid weight loss.
Black box warning: semaglutide caused thyroid C-cell tumors in rodents. Contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN2.
Risk increased when combined with insulin or sulfonylureas.
Mean increase of 2–3 bpm reported in clinical trials.
Semaglutide should not be used in the following situations:
Nausea, vomiting, diarrhea, and constipation are the most common side effects. These are most pronounced during dose escalation and typically improve over time.
Nausea is typically most intense during the first 4–8 weeks of treatment and during each dose increase. Most patients report significant improvement after 2–3 months.
Hair loss (telogen effluvium) has been reported by some patients, likely related to rapid weight loss rather than a direct effect of semaglutide.
Pancreatitis is a rare but serious potential side effect. Patients with a history of pancreatitis should not use semaglutide. Seek immediate medical attention for severe abdominal pain.
Long-term safety data from the SUSTAIN and STEP trials (up to 2 years) shows a generally favorable cardiovascular safety profile. The SELECT trial demonstrated cardiovascular risk reduction in high-risk patients.
Purgo Labs provides HPLC-verified, third-party tested Semaglutide for legitimate research purposes. Every batch includes a certificate of analysis.
Shop Semaglutide at Purgo LabsMedical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.